February 18, 2021 11:22 AM ESTUpdated 04:33 PM

Amid the 'superbug' crisis, a Big Pharma-backed fund scores a meager raise for antibiotics R&D. Is $140M nearly enough?

Nicole DeFeudis

Editor

Years after Big Pharma abandoned the antibiotics space, a small syndicate has raised $140 million to address the looming threat of antimicrobial resistance — but is …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Amid the 'superbug' crisis, a Big Pharma-backed fund scores a meager raise for antibiotics R&D. Is $140M nearly enough?

Nicole DeFeudis

Editor

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Amid the 'su­per­bug' cri­sis, a Big Phar­ma-backed fund scores a mea­ger raise for an­tibi­otics R&D. Is $140M near­ly enough?

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Amid the 'superbug' crisis, a Big Pharma-backed fund scores a meager raise for antibiotics R&D. Is $140M nearly enough?

Applied Therapeutics' rare disease drug gets a CRL

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva